View in EDS

Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity.

Saved in:
Bibliographic Details
Title: Particulate antigens administrated by intranasal and intravaginal routes in a prime-boost strategy improve HIV-specific TFH generation, high-quality antibodies and long-lasting mucosal immunity.
Authors: Vazquez T; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France., Torrieri-Damard L; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France., Pitoiset F; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France., Levacher B; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France., Vigneron J; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France., Mayr L; Université de Strasbourg, Fédération de médecine Translationnelle de Strasbourg, INSERM U1109, F-67000, France., Brimaud F; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France., Bonnet B; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France., Moog C; Université de Strasbourg, Fédération de médecine Translationnelle de Strasbourg, INSERM U1109, F-67000, France., Klatzmann D; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France., Bellier B; Sorbonne Université, UMRS 959, laboratory I(3), F-75013 Paris, France; INSERM, UMRS 959, laboratory I(3), F-75013 Paris, France; AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Biotherapies and the Clinical Investigation Center in Biotherapy, F-75013 Paris, France. Electronic address: bertrand.bellier@sorbonne-universite.fr.
Source: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2023 Oct; Vol. 191, pp. 124-138. Date of Electronic Publication: 2023 Aug 25.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 9109778 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3441 (Electronic) Linking ISSN: 09396411 NLM ISO Abbreviation: Eur J Pharm Biopharm Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-3441
DOI:10.1016/j.ejpb.2023.08.014